Translation of "Organ transplantations" in German

The invention relates to an apparatus for rejection diagnostics after organ transplantations.

How can we now concrete at organ-transplantations the repulsion-reaction prevent?

The number of organ donations and transplantations is increasing every year in Europe, thus enabling thousands of lives to be saved.

Particularly, cyclosporine A or cyclosporine B are used as immunosuppressants, in particular in organ transplantations.

One possible use of these animals is in the inhibition of transplant rejection in transgenic models of organ transplantations.

Organ transplantations are often needed, and often fail due to the limited availability of natural replacement organs.

Ministers will continue discussions and exchange views on organ donations and transplantations in the session before lunch.

The CHMP questioned the MAH's justification with regards to the listing of specific organ transplantations in the indication.

The MAH agreed with the CHMP that no specific organ transplantations should be mentioned in section 4.1 unless not appropriate to use.

However, only 41% of all Europeans have discussed with their family the question of organ donation and transplantations.

However, only 41% of all Europeans have discussed the question of organ donation and transplantations with their family.

This relates to their use as pharmaceuticals for surgical interventions, for example in association with organ transplantations, with it being possible to use the compounds for protecting the organs in the donor before and during the removal, for protecting removed organs, for example when treating them with, or storing them in, physiological bathing fluids, and also when transferring them into the recipient.

This relates to their use as pharmaceuticals for surgical interventions, for example in association with organ transplantations, with it being possible for the compounds to be used for protecting the organs in a donor before and during removal, for protecting removed organs, for example when they are being treated with, or stored in, physiological bathing fluids, and also when transferring the organs into the recipient.

SUMMARY OF THE INVENTION Proceeding from the prior art problems specified, it is the object of the invention to make available an apparatus for the rejection diagnostics after organ transplantations, which, on the one hand, is implantable for information on the condition of the transplanted organ to be obtained telemetrically at any time, but which, on the other hand, is not governed by the restrictions of the complete heart-pacemaker systems mentioned above.

Accordingly, provision is made for an apparatus for rejection diagnostics after organ transplantations which is equipped with an extracorporal base station comprising a high frequency transmitter and receiver unit.

According to the invention the therapy with fumaric acid monoalkyl esters or salts thereof may also be carried out in combination with one or more compositions of the triple drug therapy commonly used in organ transplantations or with cyclosporine A, especially for the treatment, alleviation or suppression of host-versus-graft reactions.

This is the case with regard to their use as pharmaceuticals for surgical interventions, for example in organ transplantations, where the compounds can be used both for protecting the organs in the donor prior to and during removal, for protecting organs which have been removed, for example when they are being treated with or stored in physiological bathing fluids, and when transferring the organs into the recipient.

On account of the protective actions of these substances in pathological hypoxia or ischemic situations, further possibilities of application result therefrom in surgical interventions for the protection of temporarily undersupplied organs, in organ transplantations for the protection of the removed organs, in angioplastic vascular or cardiac interventions, in ischaemias of the nervous system, in the therapy of states of shock and for the prevention of essential hypertension.

Because of the protective effects of these substances in pathological hypoxic or ischemic situations, there are further possibilities for using these compounds in association with surgical interventions, for protecting organs which are from time to time less well supplied, in association with organ transplantations, for protecting the organs which are being removed, in association with angioplastic blood vessel or cardiac surgery, in association with ischemias of the nervous system, in association with the therapy of conditions of shock, and for prophylactic prevention of essential hypertension.

Due to the protective effects of these substances in pathological hypoxic or ischaemic situations, further application, include use in surgical interventions for the protection of temporarily undersupplied organs, in organ Transplantations for the protection of the removed organs, in angioplastic vascular or cardiac interventions, in ischaemias of the nervous system, in the therapy of states of shock and for the prevention of essential hypertension.

Furthermore, they can be used in cases of organ transplantations and kidney dialysis and are useful for preventing relapse in cases of stomach ulcers.

Further, it is preferable if the autoimmune disease is selected from the group consisting of: type I diabetes mellitus, rheumatoid arthritis, multiple sclerosis, chronic gastritis, Crohn's disease, Basedow disease, Bechterew disease, psoriasis, myasthenia gravis, autoimmune hepatitis, APECED, Chrug-Strauss syndrome, ulcerative colitis, glomerulonephritis, Guillain-Barré syndrome, Hashimoto thyroiditis, lichen sclerosus, systemic lupus erythematodes, PANDAS, rheumatic fever, sarcoidosis, Sjörgren syndrome, Stiff-Man syndrome, scleroderma, Wegener's granulomatosis, vitiligo, autoimmune enteropathy, Goodpasture syndrome, dermatomyositis, polymyositis, autoimmune allergy, asthma and autoimmune reaction after organ transplantations.

In addition to oral administration, the intravenous administration of cyclosporine A is in particular also of importance, since, above all, directly after organ transplantations, an oral administration is not possible.

They are suitable for inhibition of thrombocyte aggregation, act cytoprotectively on the stomach, liver, kidneys and pancreas and therefore can be used for organ transplantations.